Chemistry:PH-797804
From HandWiki
PH-797804 is a drug which acts as a selective inhibitor of the enzyme p38 mitogen-activated protein kinase (p38 MAPK). It has antiinflammatory effects and has been researched for the treatment of inflammatory lung conditions such as chronic obstructive pulmonary disease and COVID-19. While it has not been adopted for clinical use, it remains widely used in research.[1][2][3][4][5]
See also
- NJK14047
- Pamapimod
References
- ↑ "Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation". The Journal of Pharmacology and Experimental Therapeutics 331 (3): 882–895. December 2009. doi:10.1124/jpet.109.158329. PMID 19720877.
- ↑ "Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase". Bioorganic & Medicinal Chemistry Letters 21 (13): 4066–4071. July 2011. doi:10.1016/j.bmcl.2011.04.121. PMID 21641211.
- ↑ "Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial". Thorax 68 (8): 738–745. August 2013. doi:10.1136/thoraxjnl-2012-202744. PMID 23539534.
- ↑ "Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration". PLOS Pathogens 14 (8). August 2018. doi:10.1371/journal.ppat.1007268. PMID 30161247.
- ↑ "Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier". Antiviral Research 209. January 2023. doi:10.1016/j.antiviral.2022.105475. PMID 36423831.
 |  |
